ANN ARBOR, Mich., March 27 /PRNewswire/ -- NanoBio Corporation has captured a coveted spot as a presenter at the 7th Annual InvestMidwest Venture Capital Forum. Set for April 5-6, 2006 at A.G. Edwards National Headquarters in St. Louis. The event provides a chance for presenters to share their business plans with an audience of the nation's top venture capitalists, corporate and private investors, and investment bankers.
Michael Nestor, NanoBio's CEO, is scheduled to provide an overview of the company on April 6, including details on the successful Phase II clinical trial for its lead product targeting herpes labialis, planned clinical trials for its onychomycosis (nail fungus) product, and development plans for other pipeline products.
About NanoBio Corporation:
NanoBio(R) Corporation is a biopharmaceutical company focused on developing and commercializing topical therapies based on its proprietary nanoemulsion technology for the treatment of viral, fungal, and bacterial infections. The company's initial applications target herpes labialis (cold sores) and onychomycosis (nail fungus), both of which represent multi-billion dollar markets. The company's herpes labialis product has demonstrated efficacy and safety in 332 patients in a Phase II clinical trial. Its onychomycosis product will begin a Phase II clinical trial during 2006.
External grant funding of $7 million is currently being directed towards the development of the company's third product, a mucosal vaccine that will not require refrigeration or the use of needles. In addition, pre-clinical data indicates that the company's nanoemulsion technology may also be effective against methicillin resistant staphylococcus aureus, genital herpes, herpes zoster, and respiratory infections.
NanoBio's products have inherent commercialization advantages given their well-defined development pathways and the low risk, rapid regulatory approval and cost efficiency associated with topical therapies. To date, $38 million from grants and angel investors has been invested in the company's technology.
NanoBio CorporationCONTACT: John Coffey, Vice President, Business Development of NanoBioCorporation, +1-734-302-4000, ext. 107
